The median age for the cohort with LBCL who received the infusion was 69 years (range 25–78) (Table 1); 15 had double expressor (expression of c-MYC and BCL2) LBCL, 3 had high-grade B cell lymphoma with translocation of c-MYC and BCL2 and/or BCL6 (double-hit) and 4 had previous autologous stem cell transplant. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.